ArticleJournal of applied genetics2026
Genetic analysis of autosomal dominant polycystic kidney disease in Iranian families: a combined Sanger and next-generation sequencing study.
Article in Journal of applied genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular genetic diagnosis of autosomal dominant polycystic kidney disease - A systematic review.Global medical genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder, primarily caused by mutations in the PKD1 and PKD2. Genetic testing is valuable for the diagnosis, prognosis, and clinical management of ADPKD. Next-generation sequencing (NGS) techniques can overcome the limitations of traditional Sanger sequencing for the genetic diagnosis of ADPKD. This study included 18 Iranian ADPKD families. Long-range PCR and Sanger sequencing were used to analyze PKD1 and PKD2. Subsequently, NGS-based gene panel testing and whole-exome sequencing (WES) were also performed in selected families. Pathogenic/likely pathogenic variants were identified in 13/18 families (72.2%), including 9 in PKD1 and 4 in PKD2. Five novel variants were discovered (c.10016C > A, c.2096_2097 + 4del, c.12138 + 5G > C in PKD1; c.2359-8_2373del, c.180_181delGC in PKD2). Additionally, WES revealed a pathogenic PKD1 frameshift deletion (c.11376delG) in one genetically unresolved family, likely missed by initial Sanger sequencing due to allelic dropout. This study expands the mutational spectrum of PKD1/PKD2 with five novel variants. The findings demonstrate the advantages of NGS over conventional Sanger sequencing methods. The genetically unresolved cases suggest the potential involvement of variants within non-coding regions, large copy number variations, or novel genes in ADPKD pathogenesis. Whole-genome sequencing is warranted to investigate these unresolved cases further.
Indexed as
Identifiers
39951171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.